Procaps S.A. has raised funds
Procaps S.A. has closed a club deal bank facility in a transaction financed by Bancolombia S.A. and Banco Davivienda S.A. The funds will be designated for the refinancing of existing debts owed to current creditors. This strategic allocation will empower the company to navigate its growth plan with enhanced financial strength.
Procaps S.A. is a Colombian multinational firm, leader in the pharmaceutical market. The company develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and clinical solutions. Procaps distributes its products to 50 markets.
Oaklins’ team in Chile acted as the exclusive financial advisor to Procaps S.A. in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more